John M. Burke, MD: In regard to this particular patient case example, this was an elderly patient who had relapsed 1 year after completing R-CHOP [rituximab with cyclophosphamide, doxorubicin, vincristine and prednisolone] chemotherapy. The options, in theory, would have included stem cell transplant. Right now, CAR [chimeric antigen receptor] T-cell therapy is only approved as a third-line treatment.
Certainly, there are other chemotherapy regimens that could have been chosen here. This patient would have fit into the L-MIND study criteria, having had relapsed disease and because her physician did not feel that she was transplant eligible based on her age and performance status. I think this was a reasonable choice for this patient. You could use it in the second line, or you could use it as third-line therapy or beyond.
One of the questions about this drug is whether it should be used before CAR T-cell therapy. Why? Well, the drug targets CD19. The theoretical concern is that maybe the targeting of CD19 will remove that protein from the cell, and thereby make the CAR T-cell therapy, which is also targeting CD19, ineffective. Of course, you don’t want to do that.
We don’t have a tremendous amount of data on the answer to that question. There are some in vitro data that were presented at ASH [the American Society of Hematology annual meeting] suggesting that removal of CD19 from the cells probably doesn’t happen. That has been looked at in CLL [chronic lymphocytic leukemia] as well. It does not appear that there’s a big reduction in CD19 on the surface of the cell in CLL after tafasitamab exposure. There have been a few case reports, but not a lot, on successful CAR T-cell therapy after tafasitamab. But again, the data are a bit sparse. That’s one of the theoretical concerns about using tafasitamab in the pre-CAR T-cell therapy space. We don’t yet know the answer, and hope that more data forthcoming will help us understand that impact and relationship better.
Transcript edited for clarity.
Case: A 77-Year-Old Woman With DLBCL
Initial Presentation
Clinical Work-up
Treatment
Fitting Loncastuximab Into the Current Landscape of R/R DLBCL
March 21st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.
Read More
Utilization Challenges Hold Back the Adoption of Bispecific Therapies
February 23rd 2024Bispecific antibodies are a powerful class of therapy that offer an alternative or complement to CAR T-cell therapies, but there are similar challenges to implementing them in clinical practice. In live events, experts discussed their experience setting up standard operating procedures in their cancer centers.
Read More
What is the Best Dose of Lenalidomide? Lunning Provides His Analysis in R/R DLBCL
February 16th 2024In the second part of a 2-article series, Matthew A. Lunning, DO, FACP, leads a discussion on how to best manage toxicities from tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Real-World Data Confirms Efficacy of Tafasitamab for R/R DLBCL
February 8th 2024In an interview with Targeted Oncology, Bruce Feinberg, DO, discussed the importance of real-world data, highlighting recent findings on tafasitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma in the United States.
Read More